Abstract 1653P
Background
The presence of minimal intra-pancreatic fat deposition (IPFD) in the healthy human pancreas has been demonstrated in numerous studies. But excess IPFD, leads to a wide array of diseases, including but not limited to diabetes, pancreatitis, and pancreatic cancer (PC). Remarkably, PC patients with excessive intra-pancreatic fat accumulation are commonly associated with a poor prognosis compared to those with minimal IPFD. However, the interaction between tumor and IPFD remains elusive. Here, we evaluated the pancreatic fat infiltration in normal people and patients with PC respectively, and explored how intra-pancreatic fat accelerates tumor progression.
Methods
Magnetic resonance imaging (MRI) and clinical biopsy specimens were used to assess the degree of pancreatic fat infiltration in PC patients and healthy control individuals. The KC, KPC, KCO, and AAV8-ADIPOQ-DTA mice were established to demonstrate that IPFD promoted tumor progression. The single-nucleus sequencing of pancreatic fat tissue and proteomic of PC cell lines were performed to identify the mechanism of interaction between cancer cells and adipocytes.
Results
We found that patients with PC presented excess intra-pancreatic fat deposition more frequently than control individuals, and the degree of fat infiltration was positively correlated with the tumor size of PC patients. High-fat diet KPC mice or KCO mice showed a higher degree of IPFD, which contributed to tumor growth and low survival rates of mice. Besides, the expression of uncoupling protein 1 (UCP1) was upregulated in PC patients or spontaneous tumor mice compared to normal controls. Constantly, the single-nucleus sequencing of pancreatic fat tissue of PC patients demonstrated the increase in thermogenesis features. Specifically, we revealed that PC cells improved the thermogenesis of intra-pancreatic adipose tissue, which in turn promoted PC cell proliferation.
Conclusions
We demonstrated that excess intra-pancreatic fat infiltration fuels the progression of PC, and selectively eliminating fat in the pancreas inhibits tumor growth. Mechanistically, PC cells promote the browning of adipocytes, and then the activated adipocytes enhance the proliferation and migration of cancer cells in response.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
PUMCH.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1655P - Nampt inhibitors re-sensitize MAP17 expressing pancreas tumors
Presenter: Julia Martinez Perez
Session: Poster session 22
1656P - Targeting NPC1L1 rescues anti-tumor immunity and improves immunotherapeutic efficacy in pancreatic cancer
Presenter: Houjie Liang
Session: Poster session 22
1657P - Understanding the role of SAGA and mediator in the resistance to Pdk1 deletion in PDAC
Presenter: Katarina Ondrejkova
Session: Poster session 22
1658P - Molecular subtyping of familial pancreatic ductal adenocarcinoma identifies novel pathogenic germline variants
Presenter: Julie Earl
Session: Poster session 22
1659P - The use of liquid biopsy in patients with advanced pancreatic cancer (PDAC) to guide enrollment in phase I clinical trials
Presenter: Octave Letissier
Session: Poster session 22
1660P - Squalene epoxidase promotes pancreatic cancer growth by attenuating ER stress and activating lipid rafts-regulated Src/PI3K/Akt signalling pathway
Presenter: Ruiyuan Xu
Session: Poster session 22
1661P - Precision medicine for pancreatic cancer: A clinical study validating EUS biopsies
Presenter: Joanne Lundy
Session: Poster session 22
1662P - Targeting stress granule formation as a synthetic lethality strategy for kras-induced pancreatic cancer initiation
Presenter: Patricia Santofimia
Session: Poster session 22
1663P - Role of next-generation sequencing somatic assays in patients with advanced pancreatic cancer
Presenter: Rafaela Naves
Session: Poster session 22
1664P - Italian Association for Medical Oncology (AIOM) guideline application in real-world: Multi-institutional based survey of adjuvant and first-line pancreatic ductal adenocarcinoma treatment in Italy (GARIBALDI) - survival analyses in the metastatic cohort
Presenter: Michele Reni
Session: Poster session 22